--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ABBV20260123P210
Pharmaceutical
Abbvie Inc. was incorporated in Delaware on April 10, 2012 and holds Abbott's former research-based pharmaceutical business. The company is a global, research-based biopharmaceutical company. Abbvie develops and markets advanced therapies that address some of the world's most complex and serious diseases. Abbvie's products focus on the treatment of chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and health conditions such as complications associated with chronic kidney disease and cystic fibrosis. Abbvie's promising new drug pipeline includes more than 20 compounds or indications in Phase II or Phase III development, covering important medical specialties such as immunology, virology, oncology, nephrology, neurological diseases and women's health.
